HEALTHCARE SERVICES GROUP INC (HCSG)

Services-Nursing & Personal Care Facilities · market cap $1.5B · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Healthcare Services Group Inc (HCSG) is a services-sector company with ~35,300 employees and a market cap of ~$1.715B, operating in nursing and personal care facilities with consistent annual revenues around $1.6–1.8B. Despite its core identity as a healthcare services operator, its listed pipeline includes marimastat (Phase 3, Lung Cancer), 33525 (Phase 3, Tinea Pedis), Product 55394 (Phase 3, Bacterial Vaginosis), and Test Product 49778 (Phase 2, Seborrheic Dermatitis) — a striking mismatch with its described business that warrants significant skepticism about data accuracy. The nearest catalyst is a July 22, 2026 earnings release (impact scored 5/10).

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
marimastat	Phase 3	Lung Cancer
33525	Phase 3	Tinea Pedis
Product 55394	Phase 3	Bacterial Vaginosis
Test Product 49778	Phase 2	Seborrheic Dermatitis

Price & technical context

3-month

-10.1%

6-month

+9.3%

12-month

+31.3%

52-wk range

$15.18–$25.31

vs 50-day MA

-5.9%

vs 200-day MA

+0.8%

Realized vol

40.9%

Max drawdown

-27.4%

Daily closes through 2026-09-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for HCSG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.